Communiqués de presse Archive - Page 5 of 23 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7

OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1

OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences

OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the SITC

OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”

OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of BI 765063

OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021

OSE Immunotherapeutics Announces H1 2021 Results

OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial

Précédent
1
2
3
4
5
6
7
8
9
…
23
Suivant